

## Article

# The Role of Cell Proliferation and Extracellular Matrix Accumulation Induced by Food Additive Butylated Hydroxytoluene in Uterine Leiomyoma

Yi-Fen Chiang <sup>1</sup>, Hsin-Yuan Chen <sup>1,2</sup>, Mohamed Ali <sup>3</sup> , Tzong-Ming Shieh <sup>4</sup>, Yun-Ju Huang <sup>1,5</sup>, Kai-Lee Wang <sup>6</sup> , Hsin-Yi Chang <sup>7</sup> , Tsui-Chin Huang <sup>8</sup> , Yong-Han Hong <sup>2</sup> and Shih-Min Hsia <sup>1,7,9,10,\*</sup> 

- <sup>1</sup> School of Nutrition and Health Sciences, College of Nutrition, Taipei Medical University, Taipei 11031, Taiwan; yvonne840828@gmail.com (Y.-F.C.); hsin246@gmail.com (H.-Y.C.); yjhuang@stust.edu.tw (Y.-J.H.)
- <sup>2</sup> Department of Nutrition, I-Shou University, Kaohsiung 84001, Taiwan; yonghan@isu.edu.tw
- <sup>3</sup> Clinical Pharmacy Department, Faculty of Pharmacy, Ain Shams University, Cairo 11566, Egypt; mohamed.aboouf@pharma.asu.edu.eg
- <sup>4</sup> School of Dentistry, College of Dentistry, China Medical University, Taichung 40402, Taiwan; tmshieh@mail.cmu.edu.tw
- <sup>5</sup> Department of Biotechnology and Food Technology, Southern Taiwan University of Science and Technology, Tainan 71005, Taiwan
- <sup>6</sup> Department of Nursing, Ching Kuo Institute of Management and Health, Keelung 20301, Taiwan; kellywang@tmu.edu.tw
- <sup>7</sup> Graduate Institute of Metabolism and Obesity Sciences, College of Nutrition, Taipei Medical University, Taipei 11031, Taiwan; hsinyi.chang@tmu.edu.tw
- <sup>8</sup> Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan; tsuichin@tmu.edu.tw
- <sup>9</sup> School of Food and Safety, Taipei Medical University, Taipei 11031, Taiwan
- <sup>10</sup> Nutrition Research Center, Taipei Medical University Hospital, Taipei 11031, Taiwan
- \* Correspondence: bryanhhsia@tmu.edu.tw; Tel.: +886-273-61661-6558



**Citation:** Chiang, Y.-F.; Chen, H.-Y.; Ali, M.; Shieh, T.-M.; Huang, Y.-J.; Wang, K.-L.; Chang, H.-Y.; Huang, T.-C.; Hong, Y.-H.; Hsia, S.-M. The Role of Cell Proliferation and Extracellular Matrix Accumulation Induced by Food Additive Butylated Hydroxytoluene in Uterine Leiomyoma. *Nutrients* **2021**, *13*, 3074. <https://doi.org/10.3390/nu13093074>

Academic Editor:  
Pasquapina Ciarmela

Received: 26 July 2021  
Accepted: 30 August 2021  
Published: 31 August 2021

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

**Abstract:** Leiomyoma is the most common benign uterine tumor in reproductive-age women. Increasing numbers of studies are focusing on the effects of environmental exposure on the incidence and progression of tumors. One major step taken in the food industry is the addition of food preservatives to maintain freshness. Butylated hydroxytoluene (BHT) is a synthetic phenolic antioxidant, which is widely used as an additive to develop fat-soluble characteristics, as well as in cosmetics and rubber. Previous studies also highlighted that BHT may be related to increased fibrosis capacity and carcinogenic effects. In this study, we explored the effects of the commonly used food additive BHT on leiomyoma progression, and the related mechanism. The exposure of the ELT-3 leiomyoma cell line to BHT for 48 h increased the proliferative effect. Since leiomyoma progression is related to increases in extracellular matrix (ECM) accumulation and matrix metalloproteinase (MMP), BHT could effectively increase ECM-related protein expression, as well as MMP-2 and MMP-9 protein expression. This increase in ECM, in response to BHT, may be linked to the activation of the phosphoinositide 3-kinase (PI3K)/Akt and mitogen-activated protein kinase (MAPK) signaling pathway. Through PI3K inhibition, BHT's effect on leiomyoma progression could be partially modulated. These results suggest the harmful effect of BHT exposure on leiomyoma progression may relate to PI3K modulation. However, an in vivo study is necessary to confirm these findings.

**Keywords:** butylated hydroxytoluene; leiomyoma; uterine fibroids; extracellular matrix; matrix metalloproteinase; environmental exposure

## 1. Introduction

Leiomyoma (aka uterine fibroids) are the most common benign uterine tumors in reproductive-age women, with an incidence rate of more than 70% [1,2]. Clinically, the

leiomyoma is categorized according to its location. The International Federation of Gynecology and Obstetrics (FIGO) classified the definition, submucosal myomas (FIGO type 0, 1, 2) and intramural myomas (FIGO type 3, 4, 5). Submucosal myomas were located below the endometrium, and intramural myomas were located within the uterine wall [3,4]. The main symptoms of leiomyoma are abnormal vaginal bleeding, lower abdominal pain, and bulk symptoms [5]. Recently, studies have reported links between leiomyoma and recurrent miscarriage and infertility [5,6].

Although the pathogenesis of uterine leiomyoma is still not entirely clear, one of the most commonly accepted hypotheses is the accumulation of extracellular matrix (ECM) [7,8]. Extracellular matrix deposition contributes to the amassing of symptoms and the firmness of the tumors, and studies have shown that ECM can enhance the excessive proliferation [9] of the uterine myometrium in a process called mechanotransduction [10]. The components of the ECM include collagen (COL1A1), fibronectin, and proteoglycan.

Leiomyoma cells express significantly higher levels of ECM components than normal uterine smooth muscle cells [11]. Under normal conditions, the ECM is degraded by matrix metalloproteinases (MMPs), of which MMP-2 and MMP-9 are enzymes that mainly degrade collagen [12,13]. In turn, the activity of MMPs is regulated via tissue inhibitors of metalloproteinase (TIMPs) [13,14]; therefore, the balance between MMPs and TIMPs regulates the remodeling of ECM.

With the progression of ECM deposition, intracellular signaling pathways are triggered, such as the mitogen-activated protein kinase (MAPK) and PI3K/Akt (protein kinase B (PKB)) pathways, which increase proliferation and cell survival and maintain the ECM's deposition microenvironment in leiomyoma [15,16].

Considering the rapidly increasing consumption of food additives, more and more studies are revealing their potentially harmful and toxic effects. To preserve food freshness, antioxidant additives are widely used. Butylated hydroxytoluene (BHT) is one of the most commonly used antioxidant additives, which can improve the stability of fat-soluble vitamins and cosmetics and prevent spoilage [17]. As food antioxidants, the Joint Committee of Experts from FAO/WHO point out the consumption of BHT, its acceptable daily intake (ADI) should not be higher than 0.5 mg/kg body weight [18]. In cosmetics formulations, BHT was used in a wide range, from 0.0002% to 0.5% [19]. In the pulmonary fibrosis animal model, BHT was used as a successful model, with significant endothelial injury and fibrosis phenomenon [20,21]. Additionally, BHT was found to have a systemic effect on the lung, reproductive system, liver, and kidney [17]. However, previous studies have shown that the consumption of BHT could induce lung carcinogenesis [22]. Notably, BHT's role in leiomyoma is still not clear. The aim and the novelty of this study were to investigate the role of BHT in leiomyoma progression.

## 2. Materials and Methods

### 2.1. Cell Culture and Treatments

The Eker rat-derived uterine leiomyoma ELT3 cell line was provided by Dr. Lin-Hung Wei (Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan). Cells were cultured in Dulbecco's modified Eagle medium/Ham's F-12 Medium in a 1:1 ratio (CAISSON Labs, Smithfield, UT, USA), supplemented with 10% fetal bovine serum (FBS; GIBCO, Grand Island, NY, USA), 100 units/mL penicillin (CORNING; Manassas, VA, USA), 100 µg/mL streptomycin, sodium bicarbonate (2.438 g/L, BioShop, Burlington, ON, Canada), and 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES; 5.986 g/L; BioShop) under cultured conditions (37 °C, 5% CO<sub>2</sub>) [23].

The cells were starved in serum-free medium for 24 hours and then treated with BHT in 1% FBS medium for 24, 48, and 72 h.

### 2.2. Cell Viability Assay

The effect of BHT (Sigma-Aldrich, St. Louis, MO, USA) on cell viability was analyzed using the MTT (3-[4,5-dimethyl-2-thiazolyl]-2,5-diphenyl-2H-tetrazolium bromide; Abcam,

Cambridge, MA, USA) assay. After treatments, 1 mg/mL MTT in phosphate-buffered saline was added and incubated for an additional 3 h. The formazan crystals were dissolved in 100  $\mu$ L dimethyl sulfoxide (DMSO; ECHO Chemical Co. Ltd., Taipei, Taiwan). The optical density was measured using a VERSA Max microplate reader (Molecular Devices, San Jose, CA, USA) at 570 nm and 630 nm. We used the absorbance of the control group as the denominator to calculate the cell viability percentage.

### 2.3. Colony Formation

Cells were seeded in 6-well plates (500 cells/well) and treated with different concentrations of BHT for 48 h. After 48 h, we removed the medium and replaced it with a completed medium, which we then cultured for 1 week. The colonies were fixed with methanol (Echo Chemical Co. Ltd.) and stained with 0.5% crystal violet (Sigma-Aldrich) [24]. We then added DMSO to dissolve the crystal violet and used a VERSA Max microplate reader to measure the absorbance (595 nm). We used the absorbance of the control group as the denominator to calculate the percentage changes.

### 2.4. Immunofluorescence

After the treatments, the cells were fixed in 4% paraformaldehyde (Sigma-Aldrich) for 10 minutes at room temperature, treated with 0.5% Triton X-100 in PBS for 10 minutes, and then blocked with 5% bovine serum albumin (BSA for 30 minutes at room temperature), following with previous study [25]. The cells were then incubated with anti-MMP-2 (1:200, Abcam) or anti-MMP-9 (1:200, Santa Cruz Biotechnology, Santa Cruz, CA, USA) diluted in 5% BSA overnight at 4 °C, followed by Alexa Fluor 448-goat anti-rabbit Immunoglobulin or Alexa Fluor 546-goat anti-mouse Immunoglobulin antibodies (Thermo Fisher Scientific, Waltham, MA, USA) for 1 h at room temperature. Photographs were taken under a fluorescence microscope, then Image J was used to quantify the fluorescence intensity.

### 2.5. Protein Preparation and Western Blot

Cell lysates were homogenized with ice-cold RIPA buffer containing protease (Roche, Basel, Switzerland) and phosphatase inhibitor (Roche, Basel, Switzerland). Following quantification, 30  $\mu$ g of protein was boiled for 5 minutes, then separated using 10% or 15% SDS-polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride membranes (0.22  $\mu$ m). Nonspecific binding sites were blocked with blocking buffer (5% BSA) for 1 h at room temperature, and the membranes were incubated with the primary antibodies for proliferating cell nuclear antigen (PCNA) (1:1000, Cell signaling), matrix metalloproteinase 9 (MMP-9) (1:1000, Santa Cruz Biotechnology), MMP-2 (1:1000, Abcam), collagen type I (COL1A1) (1:1000, Genetex), alpha-smooth muscle actin ( $\alpha$ -SMA) (1:1000, Genetex (Irvine, CA, USA), PI3K (1:1000, Cell Signaling Technology, Danvers, MA, USA), p-Akt (1:1000, Cell Signaling), Akt (1:1000, Cell Signaling), extracellular-signal-regulated kinase (ERK) (1:1000, Cell signaling), p-ERK (1:1000, Cell signaling), p38 MAPKinase (1:1000, Cell signaling), p-p38 (1:1000, Cell signaling), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (1:10000, Proteintech, Rosemont, IL, USA) at 4 °C overnight. The membranes were washed and incubated for 2 h with anti-rabbit/mouse IgG coupled with alkaline phosphatase (1: 10,000) and then washed with TBST buffer. The bands were detected using ECL and visualized with the eBlot Touch Imager tm (eBlot Photoelectric Technology, Shanghai, China). The values shown were normalized to the internal control GAPDH and analyzed via the ImageJ software.

### 2.6. Statistical Analysis

Data are expressed as mean  $\pm$  standard deviation. Statistical analysis was performed with Graphpad Prism version 9 (GraphPad Software, Inc., San Diego, CA, USA), using Student's *t*-test and one-way analysis of variance (ANOVA), and we used Tukey's test for post-mortem analysis. *p* < 0.05 indicates a statistically significant difference

### 3. Results

#### 3.1. Effects of BHT on Leiomyoma Proliferation

##### 3.1.1. Proliferative Effect

We used MTT as the cell proliferation assay to evaluate the changes in cell viability following BHT exposure in ELT-3 cells. The ELT-3 cells were seeded in a 96-well plate for 24 h. After starvation for 24 h, they were treated with a graded concentration of BHT (0.1–25  $\mu\text{M}$ ) for 24 and 48 h. All the concentrations used for the 48 h treatments could significantly increase leiomyoma cell viability (Figure 1A,B), indicating the potential role of BHT in leiomyoma cell viability. The doubling time of BHT treatments significantly decreased the doubling time (Figure 1C); moreover, the PCNA expression (Figure 1D) would increase after BHT treatments, showing that BHT could increase the ELT-3 cell proliferation.





Figure 1. Cont.



**Figure 1.** Butylated hydroxytoluene (BHT) effects on leiomyoma proliferation. ELT-3 cells were cultured in a 96-well plate (3000 cells/well) after starvation with a serum-free medium for 24 h. They were then treated with different concentrations of BHT for 24 and 48 h, and we performed the following assays: (A) MTT assay to evaluate the cell viability for 24 h and (B) 48 h, used doubling time formula to calculate the (C) doubling time and Western blot for (D) proliferating cell nuclear antigen (PCNA) expression; (E) colony formation assay, following culturing in a 6-well plate for the analysis of the long-term effect of different concentrations of BHT; (F) graphical representation of colony numbers and (G) absorbance percentage following BHT exposure at different concentrations. ImageJ was used to determine the colony number. \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; and \*\*\*,  $p < 0.001$ , compared with the control group. Doubling time = duration \*  $\log(2)/(\log(\text{final concentration}) - \log(\text{initial concentration}))$ .


### 3.1.2. Colony Formation

To investigate the long-term effect of BHT on ELT-3 cell proliferation and its ability to stimulate stem cell characteristics, such as colony formation, a colony formation assay was performed after BHT exposure for 48 h and the replacement of the complete medium. The results show that BHT could significantly increase colony formation (Figure 1E), as evidenced by the increased colony count assessed via image J (Figure 1F). Furthermore, we used DMSO to dissolve the staining and measure the absorbance (Figure 1G). Overall, BHT exposure could significantly enhance colony progression and leiomyoma's proliferation potential.

## 3.2. Effects of BHT on MMP Modulation

### 3.2.1. Effects of BHT on MMP-9 and MMP-2 Protein Expression Using Immunofluorescence

Immunofluorescence was used to measure the protein expression of MMP-9 and MMP-2 following 48 h of BHT exposure. The intensity of fluorescence was significantly increased in both MMP-9 and MMP-2, indicating that BHT enhanced the levels in live cells (Figure 2A–C).



**Figure 2.** Effects of BHT on MMP modulation. ELT-3 cells were cultured in DMEM/F12 medium. After serum-free starvation for 24 h, cells were treated with different concentrations of BHT for 48 h, and the following experiments were performed: (A) immunofluorescence to measure expression changes, employing graphical representations of the fluorescence intensity levels of (B) MMP-9 and (C) MMP-2. Additionally, increased (D) MMP-9 and (E) MMP-2 protein expression ( $n = 3-4$ ) are shown. \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ , compared with the control group. We used a fluorescent microscope at 40× magnification. IntDen: integrated density.


### 3.2.2. Effects of BHT on MMP-9 and MMP-2 Protein Expression Using Western Blot

Matrix metalloproteinases act as a regulator of ECM accumulation. Western blot analysis confirmed that BHT exposure could significantly increase MMP-9 (Figure 2D) and MMP-2 (Figure 2E) protein expression.

### 3.3. Effect of BHT on Extracellular Matrix Related Proteins

#### 3.3.1. Effects of BHT on ECM Related Protein Expression Using Immunofluorescence

Immunofluorescence was used to measure the protein expression of  $\alpha$ -SMA and COL1A1 following 48 h of BHT treatment. The intensity of fluorescence was significantly increased in both  $\alpha$ -SMA and COL1A1 (Figure 3A–C).




**Figure 3.** Effect of BHT on extracellular protein expression change. ELT-3 cells were cultured in DMEM/F12 medium. After serum-free starvation for 24 h, cells were treated with different concentrations of BHT for 48 h, and the following experiments were performed: (A) immunofluorescence to measure expression changes, employing graphical representations of the fluorescence intensity levels of (B)  $\alpha$ -SMA and (C) COL1A1. Additionally, increased (D)  $\alpha$ -SMA and (E) COL1A1 protein expression ( $n = 3-4$ ) are shown. \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ , compared with the control group. We used a fluorescent microscope at  $40\times$  magnification. IntDen: integrated density.

### 3.3.2. Effects of BHT on ECM Related Protein Expression Using Western Blot

The overexpression of extracellular matrix-related proteins contributes to leiomyoma progression. Therefore, we explored ECM-related protein expression in response to BHT treatments, including COL1A1 and  $\alpha$ -SMA as confirmation for previous immunofluorescence results. Our results were consistent with the fluorescence intensity results. Moreover, BHT exposure induced the significant protein expression of COL1A1 and  $\alpha$ -SMA (Figure 3D,E). Collectively, these results indicate that the BHT exposure could enhance ECM accumulation in leiomyoma.

### 3.4. PI3K/Akt and MAPK Signaling Related Protein Expression Change in BHT Induced ECM Accumulation


One of the well-known triggering factors that regulate extracellular–intracellular signaling is ECM [15]. Studies showed that activation of PI3K/Akt and MAPK signaling pathways could modulate ECM progression [26]. Therefore, we sought to explore whether BHT mediated ECM induction is accompanied by activation of the PI3K/Akt pathway. ELT-3 cells exposure with BHT for 48 h resulted in an increase in PI3K and *p*-Akt/Akt protein expression (Figure 4A,B), and in low doses, BHT could activate MAPK signaling transduction (Figure 4C,D), indicating that BHT exposure could activate PI3K/Akt and MAPK signaling pathway to increase the ECM accumulation.



**Figure 4.** The PI3K/Akt and MAPK signaling pathway involved in BHT-induced ECM accumulation. ELT-3 cells were cultured in DMEM/F12, followed by serum-free starvation for 24 h. Cells were treated with different concentrations of BHT for 48 h. Western blotting was used to explore the protein expression of (A) PI3K (B) *p*-Akt/Akt (C) *p*-ERK/ERK, and (D) *p*-p38/p38 protein expression ( $n = 3$ ). \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; and \*\*\*,  $p < 0.001$  compared with the control group. GAPDH was used as loading control.

### 3.5. The Potential Modulative Signaling Pathway in BHT Induced ECM Accumulation

PI3K inhibitor, wortmannin, was used to investigate the potential modulator of BHT on ECM accumulation. According to a previous study, PI3K acts as the important modulator of MMP-2 [27]. By using wortmannin, the results indicated that the PI3K inhibition could reverse the BHT's effect on ECM accumulation (Figure 5).



**Figure 5.** The potential modulative signaling pathway in BHT-induced ECM accumulation: (A) the flowchart shows that treated with PI3K inhibitor wortmannin for 2 h and treated with BHT for 48 h to evaluate the PI3K modulated BHT's effect in ECM accumulation. After treatment, Western blot analysis was used to evaluate the (B) PI3K, (C) MMP-9, and (D) MMP-2 protein expression. \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; and \*\*\*,  $p < 0.001$  compared with the control group. GAPDH was used as loading control.

## 4. Discussion

In this study, BHT exposure showed its ability on the progression of uterine leiomyoma by increasing the proliferation and extracellular matrix accumulation effect through PI3K/Akt and MAPK signaling modulation.

The extracellular matrix is engaged in a complex interaction with the surrounding microenvironment while providing structural support to the cell and tissue [11]. Moreover, ECM could induce signaling networks, which, in turn, induce further ECM synthesis and deposition [11]. In leiomyoma, ECM turnover and remodeling are disrupted, with the overexpression of related proteins, such as collagen, fibronectin, and  $\alpha$ -SMA [7]. The key modulator of ECM accumulation is the matrix metalloproteinase, which participates in tissue remodeling and modulated the tissue inhibitor of metalloproteinases (TIMPs) in leiomyoma [28]. Leiomyoma pathogenesis involves growth factor stimulation, with subsequent cell proliferation, inflammation, and fibrosis [29]. Several signaling pathways are involved in leiomyoma progression, including the MAPK signaling pathway, the phos-

phorylation of extracellular signal-regulated kinases (ERK), the phosphoinositide 3-kinase (PI3K)/Akt pathway, and the wingless-type (Wnt)/ $\beta$ -catenin signaling pathway [30].

The PI3K/Akt pathway participates in the regulation of mammalian target of rapamycin (mTOR), and modulates cancer cell survival, proliferation, and apoptosis, therefore playing an important role in cancer progression [24] and in leiomyoma [31].

The pathogenesis of uterine leiomyoma is still not clear, but leiomyoma growth is estrogen- and progesterone dependent, which indicated hormone dependence plays an important role in leiomyoma progression [32,33]. Studies have shown that early exposure to environmental endocrine-disrupting chemicals (EDCs) increases the risk of leiomyoma development later in life [32,34,35]. EDCs are found in sweeteners, preserved food, and food additives [36]. EDCs impart steroidogenesis [37], estrogen-like effects, and promote the development of gynecological tumors.

Food additives maintain quality, taste, and freshness [38]. For food spoilage prevention, these food antioxidant agents are one of the major classes of food additives [39]. The most commonly used category is synthetic phenolic antioxidants, such as butylated hydroxytoluene (BHT) and butylated hydroxyanisole (BHA). These food additives were approved by the US Food and Drug Administration. However, their side effects for humans are still being debated; for example, their consumption increases oxidative stress, carcinogenicity, reproductive toxicity, and DNA repair defects [40,41]. Therefore, BHT has been restricted in some food additives, but females can still be exposed via cosmetics and medicine consumption [19], in addition to exposure to rubber, plastics, and even the environment [42], with long-term effects.

Studies exploring the toxicity of BHT have been inconsistent. One study highlighted its positive effects based on its antioxidant activity, ability to increase intracellular antioxidant enzyme levels [43], and anti-cancer effects [19], while several other studies have indicated that BHT may induce kidney and liver damage [19]. Notably, BHT metabolites are related to toxicity, as shown in a study that used gas chromatography coupled to mass spectrometry (GC-MS) [44]. Based on BHT's structure, it has a greater ability to accumulate in adipose tissue and affect hormone regulation in mammary glands, as well as being transferred through the placenta [45].

BHT was found to be harmful to metabolic- and reproductive-related diseases. In reproductive disorders, the exposure of mouse Leydig cells (TM3) with BHT suppressed cellular proliferation, altered the cell cycle, and changed the cytosolic and mitochondria calcium homeostasis [46]. In addition to causing endoplasmic reticulum (ER) stress and increasing DNA damage, it further triggered the apoptosis signaling pathway, which, in turn, activated the PI3K/Akt and MAPK signaling pathways, eventually promoting carcinogenesis [46].

Antioxidant enzymes could eliminate oxidative stress. Manganese superoxide dismutase (MnSOD), on the other hand, could act as a tumor suppressor [47] and promotor [48]. MnSOD, a highly antioxidative compound, promoted metastatic effects through the upregulation of MMP-2 [49]. In lung cancer patients, MnSOD-positive tumors were related to higher MMP-2 expression and caused tumorigenesis, including proliferation and fibrosis progression [50]. Anti-oxidation or oxidative stress would regulate MMP activation [51]. High doses of MnSOD, with its ability to eliminate oxidative stress, had a tumor-suppressor effect in several cancers [52], while low doses caused no changes in oxidative stress, leading to the accumulation of reactive oxygen species (ROS) and stimulating cancer progression through increased MMP activity [49]. Incomplete ROS degradation may trigger MMP-2 activation [53], and therefore, the different effects of the antioxidant and the additive antioxidant should be considered. Our results also revealed that BHTs' effect on ECM-related protein expression may vary with different dosages—in low dosage exposures, they are most effective.


Studies showed that BHT interacts with PI3K/Akt and MAPK signaling modulation and enhances fibrosis [54]. An injection of 400 mg/kg BHT in BALB/C mice resulted in significant intestinal fibrosis and lung fibrosis within 14 days [55]. Additionally, BHT could

induce lung carcinogens and lung damage, as shown in transgenic mice with the rasH2 gene that underwent exposure with BHT for 9 weeks [56]. BHT exposure also increased collagen I, III, and V expressions and altered both the telomerase and apoptosis-related expressions, along with further epithelial cell injury. Collectively, these studies indicate that BHT potentially affects fibrosis progression [57].

In the current study, BHT's role in leiomyoma progression was explored for the first time. BHT increased proliferative effect, increased ECM-related protein expression, and induced ECM accumulation, which is essential to leiomyoma progression. Additionally, in vitro experiments showed that BHT exposure could alter protein expression, in addition to activating the PI3K/Akt and MAPK signaling pathway. The study shows, for the first time, that BHT exposure could increase the leiomyoma progression, indicating that it may participate in PI3K and MAPK signaling pathways. However, the in vitro study used could not fully explain the role of BHT in leiomyoma. The metabolites of BHT may play different roles in leiomyoma progression; therefore, further animal studies are needed to realize its effect in the future.

## 5. Conclusions

Environmental exposure to BHT could be associated with several disease disorders and disadvantages. Using the ELT-3 rat leiomyoma cell model, the results shed light on BHT's potential in enhancing leiomyoma cell proliferation, colony formation, and ECM accumulation in a mechanism that might involve modulation of PI3K/Akt and MAPK signaling pathways (Figure 6). It is the first study to explore the effect of food additives on leiomyoma progression. Further studies will be needed in the future to investigate the pro-fibroid effects of BHT metabolites in animal studies.



**Figure 6.** Schematic representation of the potential effects of BHT in leiomyoma progression. BHT could increase cell proliferative effect, modulate PI3K/Akt and MAPK signaling pathways, increase MMP enzyme and protein expression, and increase the ECM-related protein expression.

**Author Contributions:** Conceptualization, Y.-F.C. and S.-M.H.; experimentation, Y.-F.C. and H.-Y.C. (Hsin-Yuan Chen); data analysis and figure preparation, Y.-F.C.; methodology and resources, Y.-F.C., T.-M.S., Y.-J.H., Y.-H.H., K.-L.W., H.-Y.C. (Hsin-Yi Chang) and T.-C.H.; writing—original draft preparation, Y.-F.C.; writing—review and editing, Y.-F.C., M.A. and S.-M.H.; editing and approval of the final version of the manuscript, S.-M.H. All authors have read and agreed to the published version of the manuscript.

**Funding:** This study was supported by the grants (MOST 110-2628-B-038-018, MOST 109-2314-B-038-059, MOST 109-2628-B-038-015, MOST 109-2320-B-254-001 and MOST 109-2811-B-038-523) from the Ministry of Science and Technology, Taiwan, as well as grants (MOE-RSC-108RSN0005) from the Ministry of Education, Taiwan.

**Data Availability Statement:** The data presented in this study are available on request from the corresponding author.

**Conflicts of Interest:** The authors declare no conflict of interest.

### Abbreviations

|               |  |
|---------------|--|
| $\alpha$ -SMA | Alpha smooth muscle actin                                      |
| BHA           | Butylated hydroxyanisole                                       |
| BHT           | Butylated hydroxytoluene                                       |
| BSA           | Bovine serum albumin   |
| COL1A1        | Collagen, type I   |
| ECM           | Extracellular matrix   |
| EDCs          | Environmental endocrine-disrupting chemicals                   |
| h             | Hours  |
| MAPK          | Mitogen-activated protein kinase                               |
| MMP           | Matrix metalloproteinase                                       |
| MnSOD         | Manganese superoxide dismutase                                 |
| MTT           | (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) |
| PCNA          | Proliferating cell nuclear antigen                             |
| PI3K          | Phosphoinositide 3-kinase                                      |
| PKB           | Protein kinase B   |
| ROS           | Reactive oxygen species  |
| TIMPs         | Tissue inhibitor of metalloproteinase                          |

### References

- Sabry, M.; Al-Hendy, A. Medical treatment of uterine leiomyoma. *Reprod. Sci.* **2012**, *19*, 339–353. [[CrossRef](#)] [[PubMed](#)]
- Sparic, R.; Mirkovic, L.; Malvasi, A.; Tinelli, A. Epidemiology of Uterine Myomas: A Review. *Int. J. Fertil. Steril.* **2016**, *9*, 424–435. [[PubMed](#)]
- Frasca, C.; Tuzzato, G.; Arena, A.; Degli Esposti, E.; Zanello, M.; Raimondo, D.; Seracchioli, R. The Role of Pelvic Ultrasound in Preoperative Evaluation for Laparoscopic Myomectomy. *J. Minim. Invasive Gynecol.* **2018**, *25*, 679–683. [[CrossRef](#)] [[PubMed](#)]
- Munro, M.G.; Critchley, H.O.; Broder, M.S.; Fraser, I.S. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. *Int. J. Gynaecol. Obs.* **2011**, *113*, 3–13. [[CrossRef](#)]
- Barjon, K.; Mikhail, L.N. Uterine Leiomyomata (Fibroids). In *StatPearls*; StatPearls Publishing LLC.: Treasure Island, FL, USA, 2019.
- Ali, M.; Al-Hendy, A. Selective progesterone receptor modulators for fertility preservation in women with symptomatic uterine fibroids. *Biol. Reprod.* **2017**, *97*, 337–352. [[CrossRef](#)] [[PubMed](#)]
- Islam, M.S.; Ciavattini, A.; Petraglia, F.; Castellucci, M.; Ciarmela, P. Extracellular matrix in uterine leiomyoma pathogenesis: A potential target for future therapeutics. *Hum. Reprod. Update* **2018**, *24*, 59–85. [[CrossRef](#)]
- Greco, S.; Islam, M.S.; Zannotti, A.; Delli Carpini, G.; Giannubilo, S.R.; Ciavattini, A.; Petraglia, F.; Ciarmela, P. Quercetin and indole-3-carbinol inhibit extracellular matrix expression in human primary uterine leiomyoma cells. *Reprod. Biomed. Online* **2020**, *40*, 593–602. [[CrossRef](#)]
- Bulun, S.E. Uterine fibroids. *N. Engl. J. Med.* **2013**, *369*, 1344–1355. [[CrossRef](#)]
- Leppert, P.C.; Jayes, F.L.; Segars, J.H. The extracellular matrix contributes to mechanotransduction in uterine fibroids. *Obstet Gynecol. Int.* **2014**, *2014*, 783289. [[CrossRef](#)] [[PubMed](#)]
- Wight, T.N.; Potter-Perigo, S. The extracellular matrix: An active or passive player in fibrosis? *Am. J. Physiol.-Gastrointest. Liver Physiol.* **2011**, *301*, 950–955. [[CrossRef](#)]

12. Bogusiewicz, M.; Stryjecka-Zimmer, M.; Postawski, K.; Jakimiuk, A.J.; Rechberger, T. Activity of matrix metalloproteinase-2 and -9 and contents of their tissue inhibitors in uterine leiomyoma and corresponding myometrium. *Gynecol. Endocrinol.* **2007**, *23*, 541–546. [[CrossRef](#)]
13. Lin, P.-H.; Kung, H.-L.; Chen, H.-Y.; Huang, K.-C.; Hsia, S.-M. Isoliquiritigenin Suppresses E2-Induced Uterine Leiomyoma Growth through the Modulation of Cell Death Program and the Repression of ECM Accumulation. *Cancers* **2019**, *11*, 1131. [[CrossRef](#)]
14. Korompelis, P.; Piperi, C.; Adamopoulos, C.; Dalagiorgou, G.; Korkolopoulou, P.; Sepsa, A.; Antsaklis, A.; Papavassiliou, A.G. Expression of vascular endothelial factor-A, gelatinases (MMP-2, MMP-9) and TIMP-1 in uterine leiomyomas. *Clin. Chem. Lab. Med.* **2015**, *53*, 1415–1424. [[CrossRef](#)]
15. Hastings, J.F.; Skhinas, J.N.; Fey, D.; Croucher, D.R.; Cox, T.R. The extracellular matrix as a key regulator of intracellular signalling networks. *Br. J. Pharm.* **2019**, *176*, 82–92. [[CrossRef](#)]
16. Lin, P.-H.; Tung, Y.-T.; Chen, H.-Y.; Chiang, Y.-F.; Hong, H.-C.; Huang, K.-C.; Hsu, S.-P.; Huang, T.-C.; Hsia, S.-M. Melatonin activates cell death programs for the suppression of uterine leiomyoma cell proliferation. *J. Pineal Res.* **2019**, *68*, e12620. [[CrossRef](#)]
17. Yehye, W.A.; Rahman, N.A.; Ariffin, A.; Abd Hamid, S.B.; Alhadi, A.A.; Kadir, F.A.; Yaeghoobi, M. Understanding the chemistry behind the antioxidant activities of butylated hydroxytoluene (BHT): A review. *Eur. J. Med. Chem.* **2015**, *101*, 295–312. [[CrossRef](#)] [[PubMed](#)]
18. Lobo, V.; Patil, A.; Phatak, A.; Chandra, N. Free radicals, antioxidants and functional foods: Impact on human health. *Pharm. Rev.* **2010**, *4*, 118–126. [[CrossRef](#)] [[PubMed](#)]
19. Lanigan, R.S.; Yamarik, T.A. Final report on the safety assessment of BHT(1). *Int. J. Toxicol.* **2002**, *21* (Suppl. S2), 19–94.
20. Martins, V.; Teodoro, W.R.; Velosa, A.P.P.; Andrade, P.; Farhat, C.; Fabro, A.T.; Capelozzi, V.L. Butylated hydroxytoluene induces type-V collagen and overexpression of remodeling genes/proteins in experimental lung fibrosis. *Histol. Histopathol.* **2018**, *33*, 1111–1123.
21. Fujita, M.; Shannon, J.M.; Morikawa, O.; Gaudie, J.; Hara, N.; Mason, R.J. Overexpression of tumor necrosis factor-alpha diminishes pulmonary fibrosis induced by bleomycin or transforming growth factor-beta. *Am. J. Respir. Cell Mol. Biol.* **2003**, *29*, 669–676. [[CrossRef](#)] [[PubMed](#)]
22. Bauer, A.K.; Dwyer-Nield, L.D. Two-stage 3-methylcholanthrene and butylated hydroxytoluene-induced lung carcinogenesis in mice. *Methods Cell Biol.* **2021**, *163*, 153–173. [[PubMed](#)]
23. Chen, H.Y.; Huang, T.C.; Lin, L.C.; Shieh, T.M.; Wu, C.H.; Wang, K.L.; Hong, Y.H.; Hsia, S.M. Fucoidan Inhibits the Proliferation of Leiomyoma Cells and Decreases Extracellular Matrix-Associated Protein Expression. *Cell Physiol. Biochem.* **2018**, *49*, 1970–1986. [[CrossRef](#)]
24. Chiang, Y.-F.; Chen, H.-Y.; Huang, K.-C.; Lin, P.-H.; Hsia, S.-M. Dietary Antioxidant Trans-Cinnamaldehyde Reduced Visfatin-Induced Breast Cancer Progression: In Vivo and In Vitro Study. *Antioxidants* **2019**, *8*, 625. [[CrossRef](#)] [[PubMed](#)]
25. Chiang, Y.-F.; Chen, H.-Y.; Chang, Y.-J.; Shih, Y.-H.; Shieh, T.-M.; Wang, K.-L.; Hsia, S.-M. Protective Effects of Fucoxanthin on High Glucose- and 4-Hydroxynonenal (4-HNE)-Induced Injury in Human Retinal Pigment Epithelial Cells. *Antioxidants* **2020**, *9*, 1176. [[CrossRef](#)]
26. Donnini, S.; Morbidelli, L.; Tarabozetti, G.; Ziche, M. ERK1-2 and p38 MAPK regulate MMP/TIMP balance and function in response to thrombospondin-1 fragments in the microvascular endothelium. *Life Sci.* **2004**, *74*, 2975–2985. [[CrossRef](#)]
27. Wang, G.; Yin, L.; Peng, Y.; Gao, Y.; Gao, H.; Zhang, J.; Lv, N.; Miao, Y.; Lu, Z. Insulin promotes invasion and migration of KRAS(G12D) mutant HPNE cells by upregulating MMP-2 gelatinolytic activity via ERK- and PI3K-dependent signalling. *Cell Prolif.* **2019**, *52*, e12575. [[CrossRef](#)] [[PubMed](#)]
28. Shin, S.J.; Kim, J.; Lee, S.; Baek, J.; Lee, J.E.; Cho, C.; Ha, E. Ulipristal acetate induces cell cycle delay and remodeling of extracellular matrix. *Int. J. Mol. Med.* **2018**, *42*, 1857–1864. [[CrossRef](#)]
29. Ali, M.; Shahin, S.M.; Sabri, N.A.; Al-Hendy, A.; Yang, Q. 1,25 Dihydroxyvitamin D3 Enhances the Antifibroid Effects of Ulipristal Acetate in Human Uterine Fibroids. *Reprod. Sci.* **2019**, *26*, 812–828. [[CrossRef](#)]
30. Borahay, M.A.; Al-Hendy, A.; Kilic, G.S.; Boehning, D. Signaling Pathways in Leiomyoma: Understanding Pathobiology and Implications for Therapy. *Mol. Med.* **2015**, *21*, 242–256. [[CrossRef](#)]
31. Islam, M.S.; Greco, S.; Janjusevic, M.; Ciavattini, A.; Giannubilo, S.R.; D’Adderio, A.; Biagini, A.; Fiorini, R.; Castellucci, M.; Ciarmela, P. Growth factors and pathogenesis. *Best Pract. Res. Clin. Obs. Gynaecol.* **2016**, *34*, 25–36. [[CrossRef](#)]
32. Bariani, M.V.; Rangaswamy, R.; Siblini, H.; Yang, Q.; Al-Hendy, A.; Zota, A.R. The role of endocrine-disrupting chemicals in uterine fibroid pathogenesis. *Curr. Opin. Endocrinol. Diabetes Obes.* **2020**, *27*, 380–387. [[CrossRef](#)]
33. Ishikawa, H.; Ishi, K.; Serna, V.A.; Kakazu, R.; Bulun, S.E.; Kurita, T. Progesterone is essential for maintenance and growth of uterine leiomyoma. *Endocrinology* **2010**, *151*, 2433–2442. [[CrossRef](#)] [[PubMed](#)]
34. Shen, Y.; Xu, Q.; Xu, J.; Ren, M.L.; Cai, Y.L. Environmental exposure and risk of uterine leiomyoma: An epidemiologic survey. *Eur. Rev. Med. Pharm. Sci.* **2013**, *17*, 3249–3256.
35. Katz, T.A.; Yang, Q.; Treviño, L.S.; Walker, C.L.; Al-Hendy, A. Endocrine-disrupting chemicals and uterine fibroids. *Fertil. Steril.* **2016**, *106*, 967–977. [[CrossRef](#)] [[PubMed](#)]
36. Nagata, C.; Nakamura, K.; Oba, S.; Hayashi, M.; Takeda, N.; Yasuda, K. Association of intakes of fat, dietary fibre, soya isoflavones and alcohol with uterine fibroids in Japanese women. *Br. J. Nutr.* **2009**, *101*, 1427–1431. [[CrossRef](#)]

37. Krawczyk, K.; Marynowicz, W.; Gogola-Mruk, J.; Jakubowska, K.; Tworzydło, W.; Opydo-Chanek, M.; Ptak, A. A mixture of persistent organic pollutants detected in human follicular fluid increases progesterone secretion and mitochondrial activity in human granulosa HGrC1 cells. *Reprod. Toxicol.* **2021**, *104*, 114–124. [CrossRef] [PubMed]
38. Lourenço, S.C.; Moldão-Martins, M.; Alves, V.D. Antioxidants of Natural Plant Origins: From Sources to Food Industry Applications. *Molecules* **2019**, *24*, 4132. [CrossRef]
39. Union ECJOJE: Regulation (EC) No 1333/2008 of the European Parliament and of the Council of 16 December 2008 on Food Additives; 2008; Volume 354, pp. 16–33. Available online: <http://data.europa.eu/eli/reg/2008/1333/oj> (accessed on 30 August 2021).
40. Vandghanooni, S.; Forouharmehr, A.; Eskandani, M.; Barzegari, A.; Kafil, V.; Kashanian, S.; Ezzati Nazhad Dolatabadi, J. Cytotoxicity and DNA fragmentation properties of butylated hydroxyanisole. *DNA Cell Biol.* **2013**, *32*, 98–103. [CrossRef]
41. Jeong, S.H.; Kim, B.Y.; Kang, H.G.; Ku, H.O.; Cho, J.H. Effects of butylated hydroxyanisole on the development and functions of reproductive system in rats. *Toxicology* **2005**, *208*, 49–62. [CrossRef] [PubMed]
42. Liang, X.; Zhao, Y.; Liu, W.; Li, Z.; Souders, C.L., 2nd; Martyniuk, C.J. Butylated hydroxytoluene induces hyperactivity and alters dopamine-related gene expression in larval zebrafish (*Danio rerio*). *Environ. Pollut.* **2020**, *257*, 113624. [CrossRef] [PubMed]
43. Fasihnia, S.H.; Peighambaroust, S.H.; Peighambaroust, S.J.; Oromiehie, A.; Soltanzadeh, M.; Peressini, D. Migration analysis, antioxidant, and mechanical characterization of polypropylene-based active food packaging films loaded with BHA, BHT, and TBHQ. *J. Food Sci.* **2020**, *85*, 2317–2328. [CrossRef]
44. Ousji, O.; Sleno, L. Identification of In Vitro Metabolites of Synthetic Phenolic Antioxidants BHT, BHA, and TBHQ by LC-HRMS/MS. *Int. J. Mol. Sci.* **2020**, *21*, 9525. [CrossRef]
45. Pop, A.; Drugan, T.; Gutleb, A.C.; Lupu, D.; Cherfan, J.; Loghin, F.; Kiss, B. Estrogenic and anti-estrogenic activity of butylparaben, butylated hydroxyanisole, butylated hydroxytoluene and propyl gallate and their binary mixtures on two estrogen responsive cell lines (T47D-Kbluc, MCF-7). *J. Appl. Toxicol.* **2018**, *38*, 944–957. [CrossRef]
46. Ham, J.; Lim, W.; Whang, K.Y.; Song, G. Butylated hydroxytoluene induces dysregulation of calcium homeostasis and endoplasmic reticulum stress resulting in mouse Leydig cell death. *Environ. Pollut.* **2020**, *256*, 113421. [CrossRef] [PubMed]
47. Ough, M.; Lewis, A.; Zhang, Y.; Hinkhouse, M.M.; Ritchie, J.M.; Oberley, L.W.; Cullen, J.J. Inhibition of cell growth by overexpression of manganese superoxide dismutase (MnSOD) in human pancreatic carcinoma. *Free Radic. Res.* **2004**, *38*, 1223–1233. [CrossRef] [PubMed]
48. Kim, J.J.; Chae, S.W.; Hur, G.C.; Cho, S.J.; Kim, M.K.; Choi, J.; Nam, S.Y.; Kim, W.H.; Yang, H.K.; Lee, B.L. Manganese superoxide dismutase expression correlates with a poor prognosis in gastric cancer. *Pathobiology* **2002**, *70*, 353–360. [CrossRef] [PubMed]
49. Zhang, H.J.; Zhao, W.; Venkataraman, S.; Robbins, M.E.; Buettner, G.R.; Kregel, K.C.; Oberley, L.W. Activation of matrix metalloproteinase-2 by overexpression of manganese superoxide dismutase in human breast cancer MCF-7 cells involves reactive oxygen species. *J. Biol. Chem.* **2002**, *277*, 20919–20926. [CrossRef]
50. Chen, P.M.; Wu, T.C.; Shieh, S.H.; Wu, Y.H.; Li, M.C.; Sheu, G.T.; Cheng, Y.W.; Chen, C.Y.; Lee, H. MnSOD promotes tumor invasion via upregulation of FoxM1-MMP2 axis and related with poor survival and relapse in lung adenocarcinomas. *Mol. Cancer Res.* **2013**, *11*, 261–271. [CrossRef]
51. Siwik, D.A.; Pagano, P.J.; Colucci, W.S. Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. *Am. J. Physiol. Cell Physiol.* **2001**, *280*, C53–C60. [CrossRef]
52. Cirigliano, M. Bioidentical hormone therapy: A review of the evidence. *J. Women's Health* **2007**, *16*, 600–631. [CrossRef] [PubMed]
53. Qian, Q.; Wang, Q.; Zhan, P.; Peng, L.; Wei, S.Z.; Shi, Y.; Song, Y. The role of matrix metalloproteinase 2 on the survival of patients with non-small cell lung cancer: A systematic review with meta-analysis. *Cancer Investig.* **2010**, *28*, 661–669. [CrossRef]
54. Yamaki, K.; Taneda, S.; Yanagisawa, R.; Inoue, K.; Takano, H.; Yoshino, S. Enhancement of allergic responses in vivo and in vitro by butylated hydroxytoluene. *Toxicol. Appl. Pharm.* **2007**, *223*, 164–172. [CrossRef] [PubMed]
55. Parra, E.R.; Boufelli, G.; Bertanha, F.; Samorano Lde, P.; Aguiar, A.C., Jr.; Costa, F.M.; Capelozzi, V.L.; Barbas-Filho, J.V. Temporal evolution of epithelial, vascular and interstitial lung injury in an experimental model of idiopathic pulmonary fibrosis induced by butyl-hydroxytoluene. *Int. J. Exp. Pathol.* **2008**, *89*, 350–357. [CrossRef] [PubMed]
56. Umemura, T.; Kodama, Y.; Hioki, K.; Inoue, T.; Nomura, T.; Kurokawa, Y. Butylhydroxytoluene (BHT) increases susceptibility of transgenic rasH2 mice to lung carcinogenesis. *J. Cancer Res. Clin. Oncol.* **2001**, *127*, 583–590. [CrossRef]
57. Parra, E.R.; Pincelli, M.S.; Teodoro, W.R.; Velosa, A.P.P.; Martins, V.; Rangel, M.P.; Barbas-Filho, J.V.; Capelozzi, V.L. Modeling pulmonary fibrosis by abnormal expression of telomerase/apoptosis/collagen V in experimental usual interstitial pneumonia. *Braz. J. Med Biol. Res.* **2014**, *47*, 567–575. [CrossRef] [PubMed]